Drugs / molybdenum
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT07758335 Comparator | Jul 2025 → Mar 2027 expected | ulcerative colitis | National Hepatology & Tropical Medicine Research Institute | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | molybdenum | “molybdenum 15 mcg” NCT07758335 ↗ |
| Modality | Other / unclassified | “trace elements (zinc 15 mg, chromium 15 mcg, selenium 15 mcg, copper 1000 mcg, iodine 75 mcg, iron 30 mg, magnesium 2.5 mg, molybdenum 15 mcg)” NCT07758335 ↗ |
| Route | Oral | “1 tablet twice daily” NCT07758335 ↗ |